Compass Pathways Plc (CMPS) is a Healthcare · Medical Care Facilities company listed on NASDAQ. Price $15.29 (+1.93%), Market cap $1.40B, 52-week low–high $2.35 ~ $10.96.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Financial statements, price targets, institutional (13F) holdings and related news for Compass Pathways Plc are updated in real time on BlackAll Trade.
Compass Pathways Plc trades at $15.29 (+1.93%). Real-time quotes and charts are available on BlackAll Trade.
Compass Pathways Plc has a market cap of about $1.40B.
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phas